Compare Recursion Pharmaceuticals Inc (RXRX) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B), while State Street SPDR S&P Homebuilders ETF trades at $99.14. Which is the better fit depends on your goals.
| RXRX | XHB | |
|---|---|---|
Market Cap | $1.74B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $6.79 | $121.36 |
52-Week Low | $2.84 | $94.86 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, though it maintains partnerships with Genentech and Sanofi. Analyst consensus shows 40% buy ratings with institutional interest from CalSTRS increasing its stake by 64% in Q2 2026.
Outlook remains speculative with significant losses (-961.97% net margin) offset by AI-driven drug discovery potential. Key risks include cash burn and pipeline delays, while catalysts involve clinical progress. The stock offers high-risk growth exposure in TechBio, dependent on platform validation and partnership milestones.
XHB trades at $100.75, down 2.42% today, with a bearish technical signal driven by moving averages. The ETF tracks U.S. homebuilders, with recent news highlighting mixed housing data—June new home sales rose 1.6% month-over-month but existing home sales fell 2.4% (Census Bureau and WSJ, July 2026). Institutional activity shows Greenland Capital bought $17.33 million in shares, while CoreCap Advisors reduced its position by 99.3% (SEC filings, August 2026).
Outlook is cautious due to high mortgage rates and record home prices pressuring demand, though potential housing policy support offers upside. Risks include economic sensitivity and interest rate volatility. Analysts monitor affordability trends for catalyst opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
